Danish Communications Stock News

Recently, Genmab A/S expanded its investor and scientific visibility with presentations at the TD Cowen Health Care Conference in Boston and the ASCPT Annual Meeting in Denver, while also correcting prior disclosures on executive share transactions and restricted stock unit settlements at a revised price of DKK 1,867.50. Alongside a new share buy-back program of up to 342,130 shares to meet restricted stock unit obligations, Genmab attracted fresh analyst coverage and generally positive...

Jyske Bank A/S recently completed an election of employee representatives to its Supervisory Board and launched a share repurchase programme running from 5 February 2026 to 29 January 2027, through which it plans to buy back shares worth up to DKK 3.00 billion. Alongside refreshing its board-level employee representation, the bank’s commitment to a sizeable buyback underlines management’s focus on capital return and corporate governance. We’ll now examine how Jyske Bank’s sizeable share...

Vestas Wind Systems (CPSE:VWS) has drawn fresh investor attention after securing a firm order from RWE for the 1,380 MW Vanguard West offshore wind project in the United Kingdom. See our latest analysis for Vestas Wind Systems. The RWE order lands while Vestas’ 1 year total shareholder return of 57.09% contrasts with a 30 day share price return decline of 17.17% and a 3 year total shareholder return decline of 20.90%, indicating strong recent performance but a mixed longer record. If projects...

Danske Bank (CPSE:DANSKE) is back in focus after Danske Bank Asset Management and Danish Industry expanded their alternative investments mandate to nearly DKK 1.7b, which is roughly double the previous DKK 800m framework. See our latest analysis for Danske Bank. The expanded alternative investments mandate comes as Danske Bank’s 1 day share price return of 3.16% contrasts with a softer 7 day return of 2.45% and a relatively steady 90 day share price return of 8.64%, while its 1 year total...

Novo Nordisk (CPSE:NOVO B) has put oral GLP-1 treatments at center stage with a €432 million expansion of its Athlone, Ireland facility and a fresh partnership with Vivtex on next generation oral biologics. See our latest analysis for Novo Nordisk. The flurry of oral GLP-1 news, fresh trial readouts and a new share repurchase programme comes after a tougher spell for investors, with a 30 day share price return of 34.2% decline and a 1 year total shareholder return of 60.0% decline. However,...

Why Carlsberg stock is on investors’ radar Carlsberg (CPSE:CARL B) has drawn fresh attention recently as its share price performance has differed over short and longer periods. This has prompted investors to reassess how the brewer’s fundamentals line up with its current valuation. See our latest analysis for Carlsberg. Recent trading has been mixed, with a 1 day share price return of 1% decline and a 7 day share price return of 3.1% decline, alongside a 30 day share price return of 7.2% and...

If you are wondering whether ISS shares still offer value at around kr218.20, you are not alone. Many investors are asking if the current price fairly reflects the business. The stock has had a mixed run, with a 3.4% decline over the last 7 days and an 11.0% decline over the last 30 days, while the 1 year return sits at 39.2% and the 5 year return at 87.9%. Recent news around ISS has focused on its role as a large facilities services provider and how it is positioning itself with customers...

For investors wondering whether Bavarian Nordic is attractively priced at its current level or whether the recent share price leaves less room for upside, this article walks through what the numbers indicate about value. The stock last closed at kr188.25, with returns of a 4.4% decline over 7 days, a 1.7% decline over 30 days, a 2.4% decline year to date, a 12.1% gain over 1 year, a 9.6% decline over 3 years, and a 14.0% decline over 5 years. Recent headlines around Bavarian Nordic have kept...

Recent performance snapshot A.P. Møller - Mærsk (CPSE:MAERSK B) has drawn fresh investor interest after a period where the share price shows single day, week, month and past 3 months returns all in positive territory. See our latest analysis for A.P. Møller - Mærsk. That recent strength builds on wider momentum, with an 18.2% year to date share price return and a 1 year total shareholder return of 53.3%, suggesting investors are reassessing both growth prospects and risk around A.P. Møller -...

FLSmidth (CPSE:FLS) is back in focus after a cluster of board and executive changes coincided with its full year 2025 results, which showed lower sales and earnings per share compared with the previous year. See our latest analysis for FLSmidth. The recent leadership reshuffle and completion of the DKK 1,054 million buyback sit alongside a mixed price picture, with a 31.91% 90 day share price return and a 55.03% 1 year total shareholder return suggesting positive momentum after a softer past...

Novo Nordisk (CPSE:NOVO B) has entered a high-value partnership with Vivtex Corporation to develop next-generation oral biologic medicines for obesity and diabetes. The agreement focuses on turning injectable peptide therapeutics into oral treatments using Vivtex’s drug delivery platform and Novo Nordisk’s metabolic disease expertise. The collaboration aims to broaden treatment options for patients who currently rely on injectable therapies. Novo Nordisk, trading at DKK234.5 per share, has...

Carlsberg has confirmed it is considering an IPO of its India business. The company publicly acknowledged ongoing speculation around the India listing plans. The potential IPO would give investors a direct way to gain exposure to Carlsberg’s India operations. For investors watching CPSE:CARL B, the confirmation around a possible India IPO comes at a time when the shares trade at DKK969.2. The stock is up 13.6% over the past 30 days and 17.4% year to date, with a 12.3% return over 5 years...

Per Aarsleff Holding A/S reported first-quarter 2025/26 results with sales rising to DKK 6,180 million and net income reaching DKK 187 million, modestly above the prior year. Separately, PURIS announced that PAA will become a part owner in a new LiquiForce partnership, extending Per Aarsleff’s technical footprint in Canadian infrastructure rehabilitation through shared LED-light curing and lateral renewal solutions. We’ll now examine how Per Aarsleff’s higher quarterly earnings and...

TORM plc recently reported full-year 2025 results showing sales of US$1.34 billion and net income of US$285.3 million, alongside new 2026 TCE earnings guidance of US$850 million to US$1.25 billion. The board also approved a Q4 2025 interim dividend of US$0.70 per share, highlighting management’s willingness to return substantial cash to shareholders even as earnings moderated year over year. With this combination of firm 2026 TCE guidance and a sizeable Q4 dividend, we’ll now examine how the...

Major global shipping lines, including A.P. Møller - Mærsk, have halted transits through the Red Sea and the Strait of Hormuz due to heightened military activity and security risks. Maersk is rerouting vessels around the southern tip of Africa, affecting transit times, shipping capacity and freight economics across key trade lanes. This operational shift is reshaping global supply chains and is a material development for Maersk and the wider container shipping sector. For investors tracking...

CEO transition puts leadership in focus for Bavarian Nordic (CPSE:BAVA) Bavarian Nordic (CPSE:BAVA) has moved into the spotlight after announcing that long-serving CEO Paul Chaplin will step down for personal reasons. The board is now beginning the search for his successor. See our latest analysis for Bavarian Nordic. Beyond the CEO news, Bavarian Nordic’s shares have been relatively steady, with a 1-year total shareholder return of 18.16% and more muted recent share price returns around the...

Scandinavian Tobacco Group (CPSE:STG) is back in focus after its UK arm revealed a full rebrand of the XQS nicotine pouch range, featuring new packaging, a new logo and detailed flavour profile indicators. See our latest analysis for Scandinavian Tobacco Group. The rebrand lands at a time when momentum in the shares has been relatively positive, with a 30 day share price return of 6.91% and a 90 day share price return of 12.85%. This supports a 5 year total shareholder return of 28.64% at a...

Société Générale has cut its shareholding in ISS A/S (CPSE:ISS) to below 5%, triggering a regulatory disclosure of a change in major shareholder status. The move marks a shift in ISS’s ownership structure that investors may watch for potential implications for governance and market sentiment. ISS, listed as CPSE:ISS, is a global facility services provider. Changes in its major shareholders tend to catch the eye of investors who follow long contract cycles and customer retention trends. The...

ALK-Abelló A/S recently reported full-year 2025 results showing sales of DKK 6,312 million and net income of DKK 1,197 million, confirmed an 11–15% local-currency revenue growth outlook for 2026, announced an annual dividend of DKK 1.60 per share, and disclosed that EVP of R&D Henriette Mersebach will step down in February 2026 while supporting the transition. The combination of stronger earnings, growth guidance under the Allergy+ strategy, and a planned change in R&D leadership highlights...

NKT (CPSE:NKT) is in focus after its 2025 annual results, where the company reported record-high revenue, strong operational EBITDA, and a sizeable high voltage order backlog, alongside its new Charging Forward plan and 2026 outlook. See our latest analysis for NKT. The latest results and 2026 outlook have arrived after a strong run for investors, with the 1 year total shareholder return at 67.24% and the 5 year total shareholder return at 295.98%. Recent share price momentum around DKK819.5...

Why Gubra’s latest earnings are drawing fresh attention Gubra (CPSE:GUBRA) has jumped onto investors’ radars after its 2025 earnings call, where the company reported record revenue and operating profit, alongside a sizeable upfront payment from outlicensing its EM compound. See our latest analysis for Gubra. The earnings news arrives after a sharp 18.48% 1 day share price return. However, the stock still shows a 26.78% year to date share price decline and a 21.55% 1 year total shareholder...

On 20 February 2026, RWE announced a firm order with Vestas for 92 V236-15.0 MW turbines for the 1,380 MW Vanguard West offshore wind project in the UK, with Vestas supplying, delivering, commissioning, and servicing the turbines under a comprehensive multi-year agreement. This large UK offshore order highlights how Vestas’ V236 platform and service capabilities are being applied at utility scale across a major European project. We’ll now examine how securing this large Vanguard West...

What Genmab’s recent share performance may be telling investors Genmab (CPSE:GMAB) has seen its share price slip about 10% over the past month and roughly 9% over the past 3 months, which may prompt investors to reassess the biotech’s current valuation. See our latest analysis for Genmab. While the share price is around DKK1,848.5 and the 30 day and 90 day share price returns are both close to a 10% decline, the 1 year total shareholder return of about 15% alongside a weaker 3 year total...

In February 2026, Novo Nordisk reported phase 3 REDEFINE 4 data showing its CagriSema obesity injection delivered less weight loss than Eli Lilly’s Zepbound, while also outlining future high‑dose trials and ongoing REDEFINE and REIMAGINE programs across obesity and type 2 diabetes. At the same time, Novo Nordisk moved to defend its obesity and diabetes franchise with deeper Wegovy price cuts from 2027, an expanded Wegovy 7.2 mg dose in the EU, and new partnerships and pipeline assets,...